Download PDF

1. Company Snapshot

1.a. Company Description

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol.Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program.


Esperion Therapeutics, Inc.was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Show Full description

1.b. Last Insights on ESPR

The recent 3-month performance of Esperion Therapeutics, Inc. was negatively impacted by a Q4 loss, which lagged revenue estimates. The company's FY24 total revenue grew 186% year-over-year to $332.3 million, but the U.S. net product revenue grew only 48% year-over-year to $115.7 million. Additionally, Esperion's partnership with CSL Seqirus to commercialize NEXLETOL and NEXLIZET in Australia may not have generated significant revenue yet. The company's plans to study bempedoic acid in pediatric familial hypercholesterolemia may also be a long-term strategy.

1.c. Company Highlights

2. Esperion's Strong Q3 2025 Earnings: Growth Momentum Continues

Esperion's third quarter 2025 financial results demonstrated robust execution and growth momentum, with total revenue surging 69% year-over-year to $87.3 million. U.S. net product revenue increased 31% to $40.7 million, while collaboration revenue jumped 128% to $46.7 million. The company's EPS loss widened to -$0.16, relative to estimates of -$0.09. Research and development expenses rose 36% to $14.1 million, and selling, general, and administrative expenses increased 5% to $41.8 million.

Publication Date: Nov -19

📋 Highlights
  • Revenue Growth: Total revenue surged 69% YOY to $87.3M, driven by $40.7M in U.S. net product revenue (+31%) and $46.7M collaboration revenue (+128%).
  • Generic Exclusivity: Agreements with generic manufacturers prevent NEXLETOL/NEXLIZET generics from 2025–2040, securing market dominance for over a decade.
  • Guideline Validation: Bempedoic acid included in ESC/EAS guidelines, with U.S. guideline inclusion expected Q1 2026, reinforcing cardiovascular leadership.
  • International Royalty Growth: Sequential 21% rise in Daiichi Sankyo Europe royalties to $16.4M; Otsuka’s Japanese approval accelerates global expansion.
  • Financial Position: $75M equity offering (net $72.6M) supports $215–235M 2025 OpEx guidance, with projected Q1 2026 profitability excluding milestones.

Commercial Strategy Resonating with Prescribers

The company's commercial strategy is gaining traction, with prescriber engagement up and patient access expanding. Esperion has seen a significant increase in prescribers, with a split of 60% primary care physicians and 40% cardiologists. The reimbursement process is also improving, with an 87% average approval rate for Medicare coverage and an 86% approval rate for commercial coverage.

International Partners Delivering Growth

Esperion's international partners have delivered significant growth, with royalty revenue from Daiichi Sankyo Europe increasing 21% sequentially to $16.4 million. Otsuka Pharmaceutical received marketing approval for NEXLETOL in Japan, and Esperion is expanding its reach in other regional markets. The company's pipeline strategy is to expand into high-need, high-value indications, with ESP-2001 nominated as a preclinical development candidate for the treatment of primary sclerosing cholangitis.

Valuation Metrics

Esperion's valuation metrics indicate a mixed picture, with a Price-to-Sales Ratio of 1.84 and an EV/EBITDA ratio of -22.03. The company's ROE is 23.04%, indicating a relatively strong return on equity. Analysts estimate next year's revenue growth at -5.6%, which may be a concern for investors. The stock's current valuation may be factoring in some level of growth slowdown.

Guidance and Outlook

Esperion is reiterating its full-year 2025 operating expense guidance of $215 million to $235 million and expects to achieve sustainable profitability in Q1 2026, excluding milestones. The company is confident in its ability to drive sustained growth and long-term shareholder value. With a strong pipeline and expanding international presence, Esperion is well-positioned for future growth.

3. NewsRoom

Card image cap

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Dec -03

Source: defenseworld.net

Card image cap

Esperion Therapeutics, Inc. (ESPR) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov -20

Source: seekingalpha.com

Card image cap

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

Nov -18

Source: globenewswire.com

Card image cap

Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors

Nov -12

Source: seekingalpha.com

Card image cap

Esperion Therapeutics, Inc. (ESPR) Discusses Breaking the Statin Intolerance Barrier and Closing the Care Gap in Cardiovascular Health Transcript

Nov -12

Source: seekingalpha.com

Card image cap

Esperion Therapeutics: Still An Attractive Risk/Reward Narrative As The Earnings Clock Ticks Toward Profitability

Nov -10

Source: seekingalpha.com

Card image cap

ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down

Nov -07

Source: zacks.com

Card image cap

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Nov -06

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.08%)

6. Segments

Therapies

Expected Growth: 9.08%

Esperion Therapeutics' 9.08% growth is driven by increasing adoption of its oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies, particularly Nexletol and Nexlizet. Strong sales momentum, expanded payer coverage, and growing awareness among healthcare professionals contribute to the growth. Additionally, the company's strategic partnerships and ongoing clinical trials for new indications further support its upward trajectory.

7. Detailed Products

Nexletol

Nexletol (bempedoic acid) is an oral, once-daily, non-statin LDL-C lowering therapy that inhibits the ATP citrate lyase (ACL) enzyme, a key regulator of cholesterol synthesis in the liver.

Nexlizet

Nexlizet (bempedoic acid and ezetimibe) is a once-daily, oral tablet that combines the LDL-C lowering effects of Nexletol (bempedoic acid) with the cholesterol absorption inhibitor ezetimibe.

8. Esperion Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Esperion Therapeutics, Inc. operates in a highly competitive industry with many established players, which increases the threat of substitutes. However, the company's focus on developing innovative treatments for cardiovascular diseases helps to differentiate its products and reduce the threat of substitutes.

Bargaining Power Of Customers

Esperion Therapeutics, Inc. sells its products primarily to wholesalers, distributors, and pharmacies, which have limited bargaining power. The company's strong relationships with its customers and its ability to provide high-quality products reduce the bargaining power of customers.

Bargaining Power Of Suppliers

Esperion Therapeutics, Inc. relies on a limited number of suppliers for the raw materials and services necessary to manufacture its products. While the company has some bargaining power due to its size and reputation, the concentration of suppliers in the industry increases their bargaining power.

Threat Of New Entrants

The pharmaceutical industry is highly regulated, and the barriers to entry are high. However, the potential for high profits and the growing demand for cardiovascular treatments attract new entrants. Esperion Therapeutics, Inc. must continue to innovate and differentiate its products to maintain its competitive advantage.

Intensity Of Rivalry

The pharmaceutical industry is highly competitive, with many established players and new entrants vying for market share. Esperion Therapeutics, Inc. operates in a crowded market, and the intensity of rivalry is high due to the high stakes and the need to constantly innovate and improve products.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 648.63%
Debt Cost 8.39%
Equity Weight -548.63%
Equity Cost 8.39%
WACC 8.39%
Leverage -118.23%

11. Quality Control: Esperion Therapeutics, Inc. passed 6 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Esperion Therapeutics

A-Score: 5.2/10

Value: 9.0

Growth: 5.9

Quality: 6.1

Yield: 0.0

Momentum: 9.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
ANI Pharmaceuticals

A-Score: 5.0/10

Value: 4.3

Growth: 6.0

Quality: 4.4

Yield: 0.0

Momentum: 9.5

Volatility: 5.7

1-Year Total Return ->

View Full Report
Stock-Card
Phibro Animal Health

A-Score: 4.9/10

Value: 2.7

Growth: 5.2

Quality: 4.2

Yield: 4.0

Momentum: 9.5

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
OptiNose

A-Score: 4.4/10

Value: 7.4

Growth: 4.4

Quality: 5.1

Yield: 0.0

Momentum: 5.0

Volatility: 4.7

1-Year Total Return ->

View Full Report
Stock-Card
Aquestive Therapeutics

A-Score: 4.4/10

Value: 8.0

Growth: 3.7

Quality: 5.8

Yield: 0.0

Momentum: 7.5

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Evolus

A-Score: 4.1/10

Value: 9.2

Growth: 7.2

Quality: 6.2

Yield: 0.0

Momentum: 0.0

Volatility: 2.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

3.73$

Current Price

3.73$

Potential

-0.00%

Expected Cash-Flows